Canada Life’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-80,662
| Closed | -$3.25M | – | 1813 |
|
|
2026
Q1 | $3.25M | Buy |
80,662
+72,167
| +850% | +$1.56M | 0.01% | 947 |
|
|
2025
Q4 | $214K | Sell |
8,495
-9,252
| -52% | -$217K | ﹤0.01% | 1608 |
|
|
2025
Q3 | $402K | Buy |
17,747
+11,558
| +187% | +$270K | ﹤0.01% | 1633 |
|
|
2025
Q2 | $107K | Hold |
6,189
| – | – | ﹤0.01% | 1761 |
|
|
2025
Q1 | $136K | Hold |
6,189
| – | – | ﹤0.01% | 1746 |
|
|
2024
Q4 | $197K | Sell |
6,189
-1,841
| -23% | -$55.4K | ﹤0.01% | 1746 |
|
|
2024
Q3 | $232K | Sell |
8,030
-10,706
| -57% | -$396K | ﹤0.01% | 1775 |
|
|
2024
Q2 | $719K | Buy |
18,736
+2,059
| +12% | +$93.2K | ﹤0.01% | 1591 |
|
|
2024
Q1 | $981K | Buy |
16,677
+8,647
| +108% | +$551K | ﹤0.01% | 1504 |
|
|
2023
Q4 | $478K | Buy |
8,030
+689
| +9% | +$35K | ﹤0.01% | 1710 |
|
|
2023
Q3 | $279K | Buy |
7,341
+4,000
| +120% | +$176K | ﹤0.01% | 1805 |
|
|
2023
Q2 | $306K | Sell |
3,341
-891
| -21% | -$76.9K | ﹤0.01% | 1779 |
|
|
2023
Q1 | $280K | Sell |
4,232
-286
| -6% | -$16.5K | ﹤0.01% | 1819 |
|
|
2022
Q4 | $235K | Buy |
4,518
+430
| +11% | +$22.8K | ﹤0.01% | 1866 |
|
|
2022
Q3 | $278K | Buy |
4,088
+354
| +9% | +$20.9K | ﹤0.01% | 1794 |
|
|
2022
Q2 | $169K | Hold |
3,734
| – | – | ﹤0.01% | 1842 |
|
|
2022
Q1 | $202K | Buy |
3,734
+500
| +15% | +$22.1K | ﹤0.01% | 1868 |
|
|
2021
Q4 | $152K | Hold |
3,234
| – | – | ﹤0.01% | 1925 |
|
|
2021
Q3 | $107K | Hold |
3,234
| – | – | ﹤0.01% | 2040 |
|
|
2021
Q2 | $204K | Sell |
3,234
-788
| -20% | -$40.7K | ﹤0.01% | 1926 |
|
|
2021
Q1 | $171K | Hold |
4,022
| – | – | ﹤0.01% | 1988 |
|
|
2020
Q4 | $229K | Hold |
4,022
| – | – | ﹤0.01% | 1937 |
|
|
2020
Q3 | $121K | Sell |
4,022
-6,962
| -63% | -$208K | ﹤0.01% | 1996 |
|
|
2020
Q2 | $357K | Buy |
10,984
+8,242
| +301% | +$265K | ﹤0.01% | 1769 |
|
|
2020
Q1 | $73K | Hold |
2,742
| – | – | ﹤0.01% | 2040 |
|
|
2019
Q4 | $83K | Buy |
+2,742
| New | +$75.9K | ﹤0.01% | 2115 |
|
|
2019
Q3 | – | Sell |
-6,005
| Closed | -$152K | – | 1179 |
|
|
2019
Q2 | $152K | Hold |
6,005
| – | – | ﹤0.01% | 2096 |
|
|
2019
Q1 | $117K | Hold |
6,005
| – | – | ﹤0.01% | 2028 |
|
|
2018
Q4 | $76K | Hold |
6,005
| – | – | ﹤0.01% | 2235 |
|
|
2018
Q3 | $107K | Buy |
+6,005
| New | +$111K | ﹤0.01% | 2168 |
|
Other funds holding APLS
Canada Life's APLS Position: Q2 2026 in Review
Canada Life sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 80,662 shares — an estimated $3.25M sold.
Canada Life first reported a position in APLS in Q3 2018 and held it in 30 quarters. The position peaked at $3.25M in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- Canada Life reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Canada Life sold 80,662 Apellis Pharmaceuticals shares in Q2 2026, an estimated $3.25M.
- Canada Life first reported a position in Apellis Pharmaceuticals in Q3 2018 and held it in 30 quarters.
- Canada Life's Apellis Pharmaceuticals position peaked at $3.25M in Q1 2026.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on Canada Life's 13F filing for Q2 2026, filed 13 Aug 2026.